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ABSTRACT
The physiologic function of adipose tissue is altered by the host’s inﬂammatory response; the
implications for maintaining human health and regulating inﬂammation-associated disease
progression are ill deﬁned. However, this cannot be investigated in humans, therefore the use of
animal models is required. With the aim to determine morphological and molecular alterations to
perivascular and organ-associated adipose tissues during inﬂammatory arthritis, collagen-induced
arthritis (CIA) was established in male DBA/1 mice. Emerging evidence from this study signposts CIA
in the DBA/1 mouse as a model that is relevant to study the development and treatment of
early cardiovascular pathology associated with inﬂammatory arthritis. Here, we show global
morphological changes in adipose tissue and the thoracic aorta in animals induced with CIA
compared with the non-immunized controls. In CIA, we concluded that the increased cell count in
PVAT was, at least in part, caused by an ingress and/or expansion of macrophages that had a mixed
phenotype. A substantial increase of galectin-3 was expressed in PVAT from mice with CIA. Galectin-
3 is elevated in the blood of patients with CVDs, however, it has never before been measured in
PVAT in rodents or humans. Here, PVAT-associated galectin-3 is identiﬁed as a potential biomarker
for detecting early vascular pathology in CIA and a promising candidate for translation to RA.
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Introduction
The prevalence of being overweight and obesity are increas-
ing worldwide, and are also surprising features in patients
with rheumatoid arthritis (RA) that is normally associated
with hyper-catabolism or rheumatoid cachexia.1,2 Increased
fat mass is accompanied by decreased lean mass in patients
with RA.3,4 This aberrant change in fat/lean mass ratio is
associated with reduced efﬁcacy of disease modifying anti-
rheumatic drugs5 and anti-tumor necrosis factor (anti-
TNF) therapy.6 Adipose tissue is a potent source of cyto-
kines and adipokines including TNF.7 By orchestrating sys-
temic inﬂammation, disease progression and sub-optimal
therapeutic responses, the inﬂuence of adipose tissue on RA
pathology is multifaceted. Altered fat/lean body composi-
tion is also linked to hypertension, low high-density lipopro-
tein levels, insulin resistance and metabolic syndrome in
RA.8 The role of adipose tissue inmodulating RA-associated
comorbidities is likely underestimated. Although published
data are sparse and contentious, emerging evidence suggests
that the proportions and bodily distribution of fat predis-
poses individuals to diabetes, hypertension and risk for
cardiovascular disease. This study, to our knowledge, is the
ﬁrst to describe the morphology of perivascular adipose tis-
sue (PVAT), white adipose tissue (WAT) and brown adi-
pose tissue (BAT) in DBA/1 mice. This strain is widely used
to study therapeutic, pathological and immunological
responses in the collagen-induced arthritis (CIA)model; the
favored surrogate experimental model for RA. Here, CIA
was used to distinguish phenotypic changes to adipose tissue
during inﬂammatory arthritis that may well be implicit to
identifyingmodiﬁable factors for future advancement of dis-
ease management strategies.
Adipose tissue is required to fulﬁl several important
physiologic functions that include structural support, lipid
storage, thermogenesis and tissue homeostasis.9 The adipose
organ comprises 2 tissue types: white adipose tissue (WAT)
and brown adipose tissue (BAT).10,11 The function of adi-
pose tissue largely depends on its location. Perivascular adi-
pose tissue (PVAT) surrounds systemic blood vessels; it is
an abundant mixture of WAT and BAT12 and secretes
adipokines (e.g. adiponectin and leptin), cytokines (e.g.,
Interleukin-6, Interleukin-8 and TNFa) and gaseous
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molecules such as reactive oxygen species (ROS) and
H2O2.
13–17 These soluble factors regulate dilation and con-
striction responses in the vasculature 18 and modulate
immune function.19,20 Themechanisms that underlie arthri-
tis-associated cardiovascular pathologies may well be linked
to PVAT. A notion that is supported by studies in obesity
and cardiovascular disease that show PVAT’s normal inhib-
itory action on vascular constriction responses are counter-
acted by oxidative stress and inﬂammation in the adipose
tissue environment.18 Data from human studies translates
across several mammalian species (including mouse) and
animal models that also report the negative functional
impact of adipose tissue associated inﬂammation upon the
vasculature.21,22 DBA/1 mice exhibit CIA-associated con-
tractile dysfunction in the thoracic aorta.23 This study will
determine changes to PVAT morphology during CIA that
could heighten risk of developing arthritis-associated car-
diovascular pathology and dysfunction.
In patients with diabetes, hypertension and obesity
changes to adipose tissue structure are observed namely;
adipocyte hypertrophy, increased mass, altered lipid drop-
let composition and tissue inﬁltration by macrophages and
T cells.22,24 WAT is a dense network of white adipocytes
containing a single large lipid droplet with very few mito-
chondria25,26 that is characterized by the expression of sev-
eral protein markers that include the amino acid
transporter Asc-1.27 BAT, differs in morphology to WAT.
The adipocytes in BAT contain multiple lipid droplets and
higher numbers of mitochondria.25,26 BAT is characterized
and differentiated fromWAT by its expression of themito-
chondrial proton carrier uncoupling protein 1 (UCP-1)
and a member of the proton-coupled amino acid transport
(PAT) family, PAT2.28,29 PVAT is complex adipose tissue
depot termed ‘beige’ because it is composed of brown-like
white adipocytes; effectively a of mixture of WAT and
BAT.30 Like BAT, beige adipocytes express UCP-1 but
contain fewer and slightly larger lipid droplets and an
intermediate mitochondrial density that lies between
WAT and BAT.25,31 Beige adipocytes are a distinct cell
population and their primary function is reported to be
thermogenesis. Here, and to our knowledge for the ﬁrst
time, we describe PVAT, WAT and BAT changes in mor-
phology caused by CIA and measure consequential
changes inWAT, BAT and macrophage-associated molec-
ular signals in this model of inﬂammatory arthritis. This
novel approach constitutes a ﬁrst step toward the identiﬁ-
cation of early disease activity markers for therapy, diagno-
sis or prognosis of organ-associated co-morbidities for RA.
Our data identify PVAT-associated galectin-3 and M2
macrophages as novel targets to prevent, treat or detect
vascular dysfunction at the earliest stages of inﬂammatory
arthritis. This concept, if applicable to humans, has major
clinical implications.
Materials and Methods
Animals and CIA induction
All animal care and experimental procedures complied
with the United Kingdom Animals (Scientiﬁc Proce-
dures) Act 1986 in accordance with project license 30/
2928 and approved by Local Research Ethics Committee.
CIA was initiated in 8 week-old male DBA/1 mice
(n D 8) (Harlan) as described previously.23,32,33
Mice were injected intradermally under anesthetic (Iso-
ﬂurane C O2) with an emulsion consisting of type II
chicken sternal collagen (1mg/ml)(Sigma Aldrich,
C9301–5MG) and Complete Freund’s Adjuvant
(2.5mg/ml) on Day 0 and received a second identical
immunization on Day 21. Thereafter, mice were moni-
tored daily by recording hind paw diameters and scoring
macroscopic poly-articular features of CIA in each paw
(paw score: 0 D no arthritis, 1 D mild/moderate ery-
thema and swelling, 2 D severe swelling covering entire
paw, 3 D 3 joints affected by arthritis, 4 D all joints
affected by arthritis, 5D Deformed paw/ankyloses). Indi-
vidual paw scores were combined to give a comparative
daily clinical score for each mouse. Age-matched (n D 4)
na€ıve, non-immunized, male mice were used as controls
(no arthritis). Mice were killed by inhalation of rising
CO2 concentration, followed by cardiac puncture. Mice
were fed standard rodent chow and had water ad libitum.
Histological assessment of arthritis
Hind paws comprising joints of the ankle and foot were
harvested at experiment end, ﬁxed in 1% neutral buffered
formalin solution, decalciﬁed in ethylenediaminetetrace-
tic acid, processed through to parafﬁn wax, embedded
and cut into sections. Tissue sections (7mm) were cut,
mounted onto glass slides and stained using hematoxylin
and eosin (H&E). Images were acquired using ZEISS
Observer Z.1 microscope and analyzed using Zen Pro 2
computer package (ZEISS, UK). Joint tissue sections
were analyzed by 2 blinded independent observers as
described previously.32,34 Arthritis-associated histological
features were graded as follows: cellular inﬁltration of
sub-synovial tissue (0–5), synovial hyperplasia and pan-
nus formation (0–3), cell exudate in joint space (0–3)
and bone erosion (0–3). The total score of all parameters
gave the arthritis index (AI; mean § SEM reported).
Histological analysis of adipose tissues
Thoracic aorta (PVAT intact), abdominal aorta (PVAT
intact), WAT (renal and gonadal) and BAT (inter-scapu-
lar) were harvested, ﬁxed in 70% v/v ethanol and proc-
essed through to parafﬁn wax blocks. Adipose tissue
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sections were stained with H&E, visualized using light
microscopy and analyzed using Zen Pro 2 computer
package (ZEISS, UK). Areas of interest were selected,
covering 70% of each tissue type per section respectively
(PVAT, blood vessel wall, WAT and BAT) and the cell
counter Plugin (Image J) was used to calculate average
cells per mm2. The thickness (lumen to adventitia) of the
blood vessel wall was measured across 12 equidistant
regions that covered the entire vessel. Subtle fatty
changes were expressed numerically by calculating pixels
contained in lipid droplets versus total per region of
interest (expressed as percentage) using Adobe Photo-
shop Version6 in each adipose tissue section (termed
vacuolarity). All data reported as mean § SEM.
Measurements of cytokine plasma concentrations
using LEGENDplex assay
Plasma concentrations of cytokines TNF-a, IFN-g, IL-6,
IL-10, IL-4, IL-13, IL-2, IL-5, IL-9, IL-17, IL-21 and IL-
22 were determined following manufacturing instruc-
tions of the LEGENDplex assay (BioLegend, UK).
Quantitative real-time polymerase chain reaction
(qPCR)
Cellular RNA from freshly excised PVAT (thoracic and
abdominal), WAT (renal and gonadal) and BAT (inter-
scapular) was stabilized and protected using RNAlater
solution (ThermoFisher Scientiﬁc, AM7020). Tissues
were homogenized individually. RNA was isolated using
chloroform and isopropanol. A high capacity RNA-
cDNA kit (Applied Biosystems, 4387406) was used to
convert the RNA into cDNA. Samples were heated on a
thermocycler (Applied Biosystems) at 37C for 60mins
before heating to 95C to stop the reaction. The 96 well
Fast SYBR Green (Life Technologies, 4472908) D-DCᴛ
qPCR method (ViiA7 qPCR machine; Applied Biosys-
tems) was used to quantify gene expression. The follow-
ing primers were used: Asc-1 (FP: ACAGGC
CAGGATCTAAGGTG, RP: CCTCGTGGGGTCTCAA-
CATA), PAT2 (FP: CCTTCCTGAGAGTGCCAAGA,
RP: TGTCTGGAACCCGGTTATGC), galectin-3 (FP:
ACCCAACGCAAACAGGATTG, RP: TGTCCTGCTTC
GTGTTACAC), iNOS (FP: TATTTTCAGGGCTTGCG
TGG, RP: CCACCTCTCCTGGCTTGATG), CD11c
(FP: ACGCTTACCTGGGTTACTCC, RP: AAGATGA-
CAACCTTCCCCGT), Arg1 (FP: ACAAGACAGGG
CTCCTTTCA, RP: TGCCGTGTTCACAGTACTCT)
and CD206 (FP: GTTCAGCTATTGGACGCGAG, RP:
AGTTGCCGTCTGAACTGAGA). The normalization
control was b-actin (FP: TGGCACCACACCTTCTA-
CAA, RP: AGGTCTCAAACATGATCTGGGT). Results
were presented as the average change in expression (CIA
vs. na€ıve) in DBA/1 wild-type mice.
Statistical analysis
Results are presented as mean § SEM values. Differ-
ences between 2 groups were evaluated by the
unpaired Student’s t test if they passed the Kolmo-
gorov–Smirnov normality test or otherwise by the
non-parametric Mann–Whitney test as indicated. Dif-
ferences between more than 2 groups were evaluated
by Kruskal–Wallis test with Dunn’s multiple compari-
son test. P values of  0.05 denote signiﬁcant
changes. Graphical plots and statistical analyses were
performed using GraphPad Prism v5.0.
Results
Robust polyarthritis was observed in all immunized
DBA/1 mice
Animal models were used to discover new therapeutic
targets that are currently under investigation for limiting
the complex pathogenic responses instigated by adipose
tissues.35–37 We reasoned that CIA was the most appro-
priate model to study the pathophysiology of adipose tis-
sue-associated extracellular matrix remodeling during
inﬂammatory arthritis and to unmask potential targets
for modulating arthritis-associated cardiovascular dis-
ease. We observed 100% incidence of CIA in mice
immunized against collagen II and a robust inﬂamma-
tory response characterized by extensive polyarthritis
affecting all paws. Paw diameter measurements were
used to gauge joint swelling in the hind paws (Day 21
onwards). Values increased steadily over the time course
of the experiment (CIA vs. na€ıve, Fig. 1A) reaching their
maximum at termination (p < 0.001; 2.7 § 0.1 vs. 1.89
§ 0.02). Clinical score measured macroscopic disease
activity and showed CIA progression over time (Fig. 1B),
in agreement with published data.23,32,33,38 Histological
assessment of hind paws from both na€ıve and CIA mice
(Fig. 1C) revealed substantial inﬂammatory and degener-
ative pathology that was evidenced by an AI of 8.1 § 1.1
(mean § SEM; p < 0.001) compared with the non-
immunised controls (AI D 0). During CIA progression,
weight decreased from 20.3 § 0.4 g on Day 21 to 17.5 §
0.5 g at termination in arthritic mice (p < 0.001),
whereas no weight decrease was seen in non-immunized
control mice (Fig. 1D). Percentage weight lost over this
period had a positive correlation with clinical score (p <
0.01) (Fig. 1E). Plasma concentrations of the pro-inﬂam-
matory cytokines tumor necrosis factor-a (TNF-a),
interferon-g (IFN-g) and interleukin-6 (IL-6) were not
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signiﬁcantly different in CIA mice compared with the
non-CIA controls (Day 30) (Fig. 1F). Levels of anti-
inﬂammatory cytokines (e.g., IL-10, IL-4 and IL-13) and
other T-cell associated cytokines (e.g., IL-2, IL-5, IL-9,
IL-17, IL-21 and IL-22) were below detection limit of the
LEGENDplex assay in both groups (data not shown).
Pathological changes in thoracic PVAT and vessel
wall of aorta accompany CIA
The appearance of thoracic PVAT in na€ıve mice
(Fig. 2A) was reminiscent of descriptors from the
published literature namely, a network of adipocytes
with large lipid-containing vacuoles and resident
immune cells.26 CIA created an inﬂammatory envi-
ronment (Fig. 2A) in PVAT. Cell number was
increased 1.8-fold (p < 0.001; 3594 § 131 vs. 1948 §
222 cells/mm2) by CIA compared with non-immu-
nized na€ıve control mice (Fig. 2B). The increased cell
density was accompanied by the signiﬁcant reduction
in vacuolarity (p < 0.01) in thoracic PVAT (Fig. 2B).
Leukocyte inﬁltration in the arterial intima sustains
chronic inﬂammation during atherogenesis. Cell num-
ber in the vessel wall of thoracic aorta of mice was
increased 1.4-fold by CIA compared with mice with-
out arthritis (p < 0.01, 2440 § 126.8 vs. 1741 § 144
cells/mm2, Fig. 2C). Carotid intima-media thickness is
an established surrogate marker of atherosclerosis;
this measurement may not reﬂect whole arterial
changes that occur in cardiovascular pathologies like
hypertension.39 CIA did not thicken the wall of the
thoracic aorta (Fig. 2C).
Morphological changes to PVAT were not unique to
the thoracic adipose tissue depot
Tissue remodeling associated with cardiovascular disease
and aging is not uniform along the length of the aorta.40
The abdominal aorta is relatively stiffer than more proxi-
mal sites.41,42 In CIA, regional differences were deter-
mined by analyzing phenotypic changes to PVAT in the
abdominal cavity. Cell counts were signiﬁcantly
(1.9-fold) higher (p < 0.001) in CIA mice vs. the
non-arthritic controls (3445 § 197 vs. 1849 § 38.1 cells/
mm2; Fig. 3A, B). A signiﬁcant decrease (p < 0.05) in the
vacuolarity was also observed (Fig. 3B). These morpho-
logical changes were comparable with those of the tho-
racic aorta. In contrast to the thoracic aorta, there was
no detectable cell ingress into the wall of the abdominal
aorta (Fig. 3C) nor was there any difference in the thick-
ness of the vessel wall (Fig. 3C) during CIA. The abdomi-
nal aorta was marginally narrower than the thoracic
aorta.
Morphology of systemic BAT depot but not WAT
comparable to PVAT during CIA
In rodents, PVAT that surrounds the abdominal aorta is
WAT-like whereas PVAT from the thoracic aorta is
quite different and expresses some BAT genes.11 Next,
comparative histological analyses were determined in
adipose tissue sites distant from the aorta. Cell counts in
renal-WAT (p < 0.01; 3030 § 256 vs. 1783 § 53) and
gonadal-WAT (p < 0.01; 2120 § 201 vs. 978 § 94.5)
were signiﬁcantly increased in mice with CIA vs. non-
arthritic controls. Contrary to our observations in
PVAT, there was no signiﬁcant change in WAT vacuo-
larity by CIA (Fig. 4A, B). In inter-scapular BAT, cell
ingress was also signiﬁcantly (p < 0.001) increased in
CIA vs. na€ıve mice (4023 § 178 vs. 2593 § 154) and it
was accompanied by reduced vacuolarity (p < 0.001;
Fig. 4C).
Atherogenesis-associated tissue remodeling markers
induced by CIA in PVAT
Brown adipocytes reside in BAT as well as WAT depots
and in mice the activation of BAT lowers atherogenic-
lipoprotein levels, protects against atherosclerosis devel-
opment43 and confers beneﬁcial effects on adiposity,
insulin resistance and hyperlipidaemia.44 Since systemic
inﬂammation leads to marked adipose tissue remodeling
we questioned whether CIA altered the so-called ‘brown-
ness’ of PVAT. Expression of the WAT marker Asc-1
Figure 1. CIA was successful induced in male DBA/1 mice (A) Paw diameter was measured throughout the progression of arthritis
in CCIA mice (). –CIA (dashed line) is equal to average paw diameter scores of non-immunized control mice at termination. (B) Clini-
cal Score was calculated throughout progression of arthritis and with a maximum severity limit of 14. –CIA (n D 4), CCIA (n D 8).
(C) Severity of arthritis of –CIA (n D 8) and CCIA (n D 16) hind paws was histologically assessed through calculation of arthritic index
(AI). Representative –CIA paw AI D 0: cellular inﬁltration (0–5), synovial hyperplasia (0–3, bone erosion (0–3) and cellular exudate (0–3).
Representative CCIA paw AI D 10: cellular inﬁltration (4–5), synovial hyperplasia (2–3, bone erosion (2–3) and cellular exudate (2–3).
M: 1st metatarsal, N: navicular, T: talus, JS: joint space, PF: pannus formation, E: bone erosion, CI: cellular inﬁltrate. SH: synovial hyperpla-
sia. Scale bar D 200mm (D) Weight was monitored daily during arthritis progression in –CIA (n D 4) and CCIA (n D 8) mice with an
adverse severity limit of 20% weight loss. (E) Correlation between percentage weight decrease and clinical score in CCIA mice (n D 8).
(F) Plasma concentration of pro-inﬂammatory cytokines were measured to assess the systemic inﬂammatory nature of the CIA model.
Data expressed mean § SEM.  D p < 0.001.
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was signiﬁcantly decreased by CIA in thoracic PVAT,
abdominal PVAT and inter-scapular BAT vs. na€ıve mice
(Fig. 5A). CIA augmented the expression of the BAT
marker PAT2 in inter-scapular adipose tissue (Fig. 5B).
PVAT-associated PAT2 was unaffected by CIA. CIA did
not alter renal and gonadal WAT expression of Asc-1 or
PAT2. Modiﬁcations to adipose tissue architecture are
not limited to cell ingress or proliferation and adipocyte
Figure 2. Morphological characterization of thoracic PVAT in DBA/1 na€ıve and CIA mice (A) Representative images of –CIA and CIA tho-
racic aortaC PVAT show differences in morphology between the non-arthritic and arthritic mice. Scale barD 100mm. (B) Total cell num-
ber and (C) vacuolarity was analyzed in thoracic PVAT. In the thoracic aorta, (D) total cell number and (E) vessel thickness were
measured. –CIA (n D 4), CCIA (n D 8). Data expressed as mean § SEM.  D p < 0.001,  D p < 0.01.
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hypertrophy, hyperplasia and differentiation but include
extracellular matrix (ECM) remodeling. Next galectin-3
(Gal-3) was measured as a global marker of ﬁbrosis,
angiogenesis, inﬂammation and atherogenesis that is
associated with cardiovascular risk.45–47 Gal-3 was signif-
icantly increased by CIA in PVAT but more so in tissue
from the thoracic vs. abdominal aorta. Gal-3 expression
by WAT and BAT was comparable in CIA and na€ıve
mice (Fig. 5C). Adipose tissue contains a heterogeneous
array of cells including pre-adipocytes, adipocytes and
macrophages (resident and inﬂammatory) that orches-
trate ECM remodeling. We ﬁnally asked whether CIA
Figure 3. Morphological characterization of abdominal PVAT in DBA/1 na€ıve and CIA mice (A) Morphological differences in abdominal
PVAT between na€ıve and CIA mice shown in representative images. Scale bar D 100mm. (B) Abdominal PVAT total cell number and (C)
vacuolarity were determined in –CIA and CCIA mice. (D) Total cell number and (E) vessel thickness were measured in the abdominal
aorta. –CIA (n D 4), CCIA (n D 8). Data expressed as mean § SEM.  D p < 0.001,  D p < 0.05.
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altered the phenotype of adipose tissue-associated mac-
rophages. Overall, CIA exerted ﬂuctuating increases of
M1 proﬁling genes (iNOS and CD11c) across the adipose
tissues tested, except for abdominal PVAT and BAT
where no change was observed (Fig. 6A, B). CIA caused
a profound increase in M2 proﬁling genes (Arg1 and
CD206) in thoracic PVAT but not in other adipose tissue
sites. A subtle but signiﬁcant change in Arg-1 was noted
in abdominal PVAT and renal WAT (Fig. 6C, D).
Discussion
RA is a strong risk factor for the development of car-
diovascular disease (CVD), however, the pathophysio-
logical mechanisms of arterial complications in RA
remain to be fully elucidated. Identifying early
markers of vascular damage identiﬁes a critical step
toward the development of preventative strategies
against cardiovascular complications in patients with
RA. In obesity, dysfunctional and inﬂammatory adi-
pose tissue impacts upon the cardiovascular system
and contributes to CVD. It is unclear whether this is
also the case in RA or indeed if the fat accumulation
around the vasculature has a role in the pathogenesis
of RA-associated vascular dysfunction. These ques-
tions are challenging, if not impossible, to resolve in
human subjects due to the heterogeneous clinical pre-
sentation of RA patients with CVD and the limited
sensitivity of conventional diagnostic for the early
detection of developing vascular pathology. This arti-
cle reveals mechanisms that link CIA and PVAT-
associated inﬂammation that could well initiate
vascular dysfunction and CVD during inﬂammatory
arthritis in humans.
PVAT is in intimate contact with large, medium and
small diameter arterial beds in several tissues, controls
vascular function and remodeling and has unique fea-
tures that impact vascular biology. In CIA, PVAT was
distinguished from other types of adipose tissue by
inﬂammatory and morphological changes that were, to a
large extent, independent of the visceral adipose tissue
and BAT. Increasing epidemiological and clinical evi-
dence demonstrate that perturbations in adipose tissue
quality modulate cardio-metabolic disease. This study
justiﬁes the application of CIA model, in DBA/1 mice at
least, to study PVAT function during inﬂammatory
arthritis and for the discovery and development of pre-
ventive strategies, novel diagnostic tools and new targets
Figure 4. Characterization of renal WAT, gonadal WAT and inter-scapular BAT in DBA/1 na€ıve and CIA mice. Representative images, total
cell number and vacuolarity was analyzed in non-vasculature associated sites in –CIA and CCIA mice: (A-C) Renal WAT (D-F) Gonadal
WAT (G-I) Inter-scapular BAT. –CIA (n D 4), CCIA (n D 8). Data expressed as mean § SEM.  D p < 0.001,  D p < 0.01.
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for therapy for combatting arthritis-associated cardiovas-
cular disease.
We showed that mice with CIA exhibited PVAT,
WAT and BAT morphology that was different from
na€ıve, non-immunized controls. The different origins of
the progenitor cells from which each fat depot develops
may explain the divergent tissue characteristics triggered
by CIA.48,49 To our knowledge, this is the ﬁrst report
that documents the profound effect of CIA on adipose
tissue composition most particularly with respect to the
universal increase in the cell density across all the adi-
pose tissue sites and the striking consistency of the
Figure 5. Compositional and tissue remodelling analysis of PVAT, WAT and BAT in –CIA and CCIA DBA/1 mice. The expression of (A)
WAT marker ASc-1, (B) BAT marker PAT2 and (C) tissue remodeling marker Galectin-3 were analyzed through qPCR in –CIA (n D 3 (Asc-
1 and PAT2), n D 6 (Galectin-3)) and CCIA mice (n D 3 (Asc-1 and PAT2), n D 11 (Galectin-3)). Data is expressed as fold change relative
to –CIA mice, mean § SEM. Housekeeping gene D b-actin.  D p<0.001,  D p<0.01,  D p<0.05.
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Figure 6. Analysis of M1 and M2 markers in PVAT, WAT and BAT sites of –CIA and CCIA DBA/1 mice. The expression of M1 markers: (A)
iNOS and (B) CD11c, and M2 markers: (C) Arg1 and (D) CD206 were analyzed through qPCR in –CIA (n D 6 (iNOS and Arg1), n D 8
(CD11c and CD206)) and CCIA (n D 11 (iNOS and Arg1), n D 16 (CD11c and CD206)). Data is expressed as fold change relative to –CIA
mice, mean § SEM. Housekeeping gene D b-actin.  D p < 0.001,  D p < 0.01,  D p < 0.05.
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change that ranged from 1.6 to 2.2-fold for inter-scapular
BAT and gonadal WAT respectively. These changes
reﬂect the systemic inﬂammatory nature of this arthritis
model. However, there may be several additional reasons
for the increase in cell number observed in CIA. Fat con-
sists mostly of adipocytes but also pre-adipocytes, endo-
thelial cells, ﬁbroblasts, mesenchymal cells, macrophages
and other leukocytes. Therefore adipocyte hyperplasia,
expansion of the resident macrophage population and/or
adipose tissue inﬁltration by leukocytes may also modify
the architecture of adipose tissue during CIA. This type
of hyper-cellular phenotype was previously assigned to
region-speciﬁc alterations in adipose tissue function,
metabolic proﬁle and inﬂammatory milieu in both ani-
mal models and clinical studies related to obesity.35,50–53
Indeed in obesity and type 2 diabetes, diseases also char-
acterized by a state of chronic inﬂammation, the expan-
sion of metabolically-active adipose tissues lead to local
and systemic inﬂammation, insulin resistance and altera-
tions in lipids, blood pressure, coagulation and ﬁbrinoly-
sis all of which cause endothelial dysfunction,
atherosclerosis and cardiovascular disease.54,55 Although
CIA-associated changes in WAT and/or BAT function
were not tested and are as yet undetermined; we recently
reported aberrant PVAT-dependent aortic constriction
responses in CIA vs. na€ıve age-matched DBA/1 mice.56
Control of peripheral resistance through contraction and
relaxation of constituent vascular smooth muscle is a
critical function of muscular arteries and arterioles in
vivo. PVAT is anatomically co-localized with atheroscle-
rotic lesions in humans (correlating with plaque burden
and vascular calciﬁcation). The emerging evidence from
our studies signpost CIA in the DBA/1 mouse as a model
that is relevant to study the development and treatment
of early cardiovascular pathology associated with inﬂam-
matory arthritis.23,56
Anatomical changes to the aorta by CIAwere localized to
the thoracic compartment where cell counts were increased
in the vessel wall. Leukocytes are normally present in the
adventitia of the non-diseased artery wall, however, num-
bers increase as atherosclerotic plaques develop.57 There are
structural and functional differences between the thoracic
and abdominal aorta that are inherent and that also develop
during cardiovascular disease and with aging.58 Changes to
the anatomy of the thoracic and more distal sections of the
aorta by CIA could help identify sites susceptible to calciﬁca-
tion and wall stiffening during inﬂammatory arthritis and
unmask underlying mechanisms. CIA caused increased
expression of macrophage-associated markers, primarily
pro-inﬂammatoryM1 phenotype, in both gonadal and renal
visceral WAT depots but not in the inter-scapular BAT.
Data from the Framingham Heart Study and human tissue
specimens found signiﬁcantly greater association between
vascular inﬂammation, cardiometabolic risk proﬁles and
atherogenic gene expression in visceral vs. subcutaneous
fat.51,59–62 Together these ﬁndings evidence of the value
studying multiple adipose tissue depots in the CIA model
for basic research in cardiology.
PVAT was given critical consideration in the CIA
model as it was thought to be the major fat depot for
identifying changes in vascular pathology and one
that would be most useful for predicting early CVD
during inﬂammatory arthritis. In humans, PVAT is
anatomically co-localized with atherosclerotic lesions
(correlating with plaque burden and vascular calciﬁca-
tion) and the degree of PVAT inﬂammation correlates
with cardiovascular disease.63 In CIA, we concluded
that the increased cell count in PVAT was, at least in
part, caused by an ingress and/or expansion of mac-
rophages that had a mixed phenotype. The selected
markers were not exhaustive but sufﬁcient for distin-
guishing classically activated or M1 type (CD11c and
iNOS) from alternatively activated or M2 type (Arg1
and CD206); all except iNOS were signiﬁcantly ele-
vated in PVAT by CIA. Recent studies of an experi-
mental model of endotoxin shock showed that iNOS
deﬁciency resulted in more severe inﬂammation with
an enhanced M1 macrophage activation phenotype
and that iNOS expressed by M1 macrophages reduced
M1 macrophage differentiation.64 Our data reveals the
absence of an important negative regulatory pathway
during CIA. The apparent inability of PVAT-associ-
ated macrophages to increase iNOS expression during
arthritis may be an important early trigger for devel-
opment of CVD and a mechanism that warrants fur-
ther investigation in future studies. Whereas M1
macrophages are pro-inﬂammatory, M2 macrophages
are associated with responses to anti-inﬂammatory
reactions, tissue remodeling and ﬁbrosis. CIA-associ-
ated tissue remodeling in PVAT was ﬁrst evidenced
by a substantial reduction in the expression of the
WAT marker Asc-1. The inhibitory effect of inﬂam-
mation on adipogenesis is relatively well character-
ized; pro-inﬂammatory macrophages are considered
to be the main effectors.65 PAT2 was unaltered by
CIA, this result is contrary to reported impairment of
brown adipogenesis by macrophages.66 This may sim-
ply be explained by the distinct phenotype of PVAT
vs. adipose tissues from other anatomic locations and,
the added complexity, that in rodents and perhaps
humans it comprises both BAT and WAT.12,67,68
Never-the-less a consensus is emerging that PVAT is
a cause of cardiovascular disease.69 PAT2 and Asc-1
are selective markers for brown/beige and white adi-
pocytes in human tissue and may be important fac-
tors in determining how PVAT inﬂuences focal
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vascular pathophysiology in rodent models and in
humans.
Finally, a substantial increase of galectin-3 expres-
sion by CIA was measured in thoracic PVAT com-
pared against abdominal PVAT, WAT and BAT
depots. Galectin-3 levels are elevated in the blood of
patients with CVDs, however, it has never before
been measured in PVAT in rodents or humans.
Galectin-3 concentrations in the circulation are asso-
ciated with incident heart failure, atrial ﬁbrillation,
atherosclerosis and mortality.47,70,71 The clinical util-
ity of measuring galectin-3 for CVD prediction has
not been tested in blood or indeed in PVAT. Here,
PVAT-associated galectin-3 is identiﬁed as a good
biomarker for detecting early vascular pathology in
CIA and a promising candidate for translation to
RA; an idea underpinned by the knowledge of its
critical role in, macrophage chemotaxis, phagocyto-
sis, neutrophil extravasation, oxidative stress, apo-
ptosis, and angiogenesis that in turn trigger
cardiometabolic traits such as adiposity, insulin
resistance, and hyperglycemia.
In conclusion, circulating galectin-3 concentrations
are associated with the clinical outcomes in patients with
CVD and RA.47,70–72 This study identiﬁes CIA as a
model to assess the clinical utility of galectin-3 determi-
nation for CVD prediction in patients with RA. The
development of therapeutic agents that target galectin-3
may be important to prevent or halt RA-associated
CVD. Here we evidence CIA in DBA/1 mice as a rele-
vant, justiﬁable in vivo model for conducting pre-clinical
assessments of new innovative therapies for the treat-
ment of RA-associated CVD.
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